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Brain metastases (BM) frequently occur in non-small cell 
lung cancer (NSCLC) patients. Approximately 10–20% 
of NSCLC patients already have BM at initial time of 
NSCLC diagnosis and around 40% will develop BM 
during the course of their disease (1). Known risk factors 
for the development of BM are adenocarcinoma histology, 
advanced nodal status, tumour stage and younger age (2-5). 
The recommendation to screen for asymptomatic 
BM during NSCLC staging varies in current guidelines: 
all guidelines advise to screen stage III patients, but the 
recommendation for the earlier stages (I and II) differs (6-10) 
(Table 1). Preferred screening is with gadolinium enhanced 
magnetic resonance imaging (MRI) which is superior to 
a contrast-enhanced computed tomography (CE-CT) in 
detecting presence and especially number of BM (11-13).
Although MRI is more sensitive than a CE-CT, in daily 
practice CE-CT is often used because of contra-indications 
to MRI or poor MRI accessibility (14,15). Screening 
patients for BM is important, as a diagnosis of BM will 
change the treatment plan for a patient with otherwise 
early stage disease: either the treatment with radical intent 
is abandoned and systemic treatment (with/without local 
treatment for the BM) is initiated, or both the thoracic 
disease and the BM (when few in number) are treated with 
radical intent. Besides the implications for treatment, a 
diagnosis of BM can also have a negative impact on the 
quality of life (16). 
As there is still limited data on incidence of BM in 
otherwise early stage NSCLC, we read with interest the 
article of Hudson et al., published in Ecancermedicalscience (17). 
This retrospective single centre study, performed in the 
United Kingdom, evaluated the percentage of NSCLC 
patients that had BM before, or developed BM following 
curative intent NSCLC surgery. Because brain imaging 
was not routinely performed preoperatively,  they 
also hypothesized how many BM that were detected 
postoperatively in patients without brain imaging before 
surgery, could have been detected by preoperative MRI by 
using a calculation method that used a volume doubling 
time of about 60 days. The maximum tumour diameter 
measured on the diagnostic scan was plotted against 
the number of days after surgery that the imaging was 
performed. The lesions that fell above the detection limit 
of MRI at the day of surgery were classified as likely visible 
had a pre-operative MRI been performed.
Four hundred and seventy-one NSCLC patients were 
included between January 2012 and December 2014. Five 
(1.1%) patients had neurological symptoms that led to brain 
imaging before surgery. These patients were treated with 
radical intent for their BM and local NSCLC. Another 18 
(3.8%) were diagnosed with BM after surgical resection 
of their primary lung cancer, nine (50%) already within a 
year. Four of these nine patients had only a cranial relapse. 
Of these 18 patients, the postoperative stage was I in five 
(28%) patients, II in six (33%) patients and III in seven 
(39%) patients. Twelve (67%) out of these 18 patients had 
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an adenocarcinoma. Fifteen of the BM patients were used 
for the calculation to evaluate whether their BM could have 
been visible on preoperative MRI. The other three patients 
were excluded from the analyses because two developed 
BM at over two years postsurgery, and one because 
information about timing of the BM was missing. The 
calculation method predicted that 3.3–3.8% (dependent on 
the detection threshold) of patients who underwent surgery 
already would have had BM detected by preoperative MRI 
(i.e., almost all or all patients that were diagnosed with BM 
postoperative would have been diagnosed when a MRI had 
been made preoperative). 
Based on these results, the authors suggest that NSCLC 
patients should undergo preoperative brain MRI, regardless 
of stage, especially when they are diagnosed with an 
adenocarcinoma.
Should we indeed screen all neurologically asymptomatic 
early stage NSCLC for BM? And how to put these results 
into the context of existing literature?
The calculation method the authors use is interesting 
and hypothesis generating. However, as the authors 
already state, this cannot substitute for real brain imaging 
performed before surgery. Unfortunately, the percentage of 
patients with baseline or standard follow-up brain imaging 
was not known. Information on the percentage of patients 
with extracranial early stage NSCLC, but with BM that 
precluded surgery for their extracranial disease would have 
been helpful, as these patients were not included in the 
current study. Even in early stage NSCLC, the exact stage 
seems important in the decision making whether MRI of 
the brain has to be incorporated in the staging. This is 
reflected in the number of patients with stage IIIA NSCLC 
among the patients that developed BM after surgery. 
What would have been useful additional information is 
the percentage of stage I, II and III disease patients and 
information on the specific histology (adenocarcinoma 
vs. others) that was included in the study to calculate the 
percentage of patients for each stage and histology that 
developed BM after curative intent surgery. The importance 
of the exact stage is also reflected in other studies. When, 
during staging, otherwise early stage NSCLC patients 
are screened, the reported incidence of asymptomatic BM 
depends especially on the stage, with an increase from 0–1% 
in stage IA to 21% in stage IIIA (18-20). For example, 
when using the data available from the National Lung 
Screening trial, one in eight of the patients with clinical 
stage IA underwent brain imaging (MRI or CT), but none 
had intracranial metastases (18). Another retrospective 
analysis demonstrated that even with MRI screening, the 
incidence of BM in resectable NSCLC patients was low, 
with 0% in N0-disease, 5.2% in N1-disease and 4.7% 
in N2-disease (19). Finally, a prospective study (N=91) 
showed that with screening the incidence of BM in patients 
with large cell or adenocarcinoma type NSCLC was low 
in stage I/II (3%) but increased in stage IIIA (21%) (20). 
The percentages described in these studies mirror the 
Table 1 Overview of screening recommendations for brain metastases in NSCLC guidelines
Guideline, year
Advised imaging 
method
NSCLC stages advised to screen for BM [evidence level (EL)]
Brain follow up advised after 
completion of therapy with 
curative intent?
ESMO, early stage 
and locally advanced 
NSCLC 2017 (6)
MRI, optional CE-CT Stage I–II: might be useful; stage III: mandatory (3B) Not specified
NCCN version 4. 
2018 (10)
MRI Stage IA: not advised; stage IB: optional;  
stage II–III: mandatory (2A)
Not routinely indicated
NICE, 2011 (9) MRI or CE-CT All stages when eligible for therapy with curative intent:  
consider screening, especially stage III (EL not mentioned)
Not mentioned
BTS, 2010 (7) MRI or CE-CT All stages when eligible for therapy with curative intent:  
consider screening, especially stage III (C)
Not mentioned
ACCP, 2013 (8) MRI or CE-CT if MRI 
is not available
Stage III and IV routine imaging, even when a negative clinical 
evaluation (2C) 
Biannual brain MRI mentioned 
but not recommended
ESMO, European Society for Medical Oncology; NCCN, National Comprehensive Cancer Network; NICE, National Institute for Health and 
Care Excellence; BTS, British Thoracic Society; ACCP, American College of Chest Physicians; NSCLC, non-small cell lung carcinoma; 
MRI, magnetic resonance imaging; CE-CT, contrast enhanced-computer tomography; BM, brain metastases.
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Schoenmaekers et al. Screening for BM in early stage NSCLC
percentages found in the study of Hudson et al., with a very 
low percentage in stage I disease. 
As mentioned earlier, MRI is advised for screening, 
however access to MRI can be problematic (causing a delay 
to surgery) (14,15). Discovering asymptomatic BM in early 
stage NSCLC before surgery could change the treatment 
plan, but this should be weighed against a possible delay 
to surgery and the higher costs of screening all early stage 
patients to identify a few patients with BM. The additional 
costs for a staging MRI brain are high as it was shown that 
32% of the staging costs were dedicated to brain MRI (21).
Moreover, in stage III NSCLC 13 % of patients with a 
negative staging MRI developed symptomatic BM within a 
year of a staging MRI without suspicious findings (22). In 
stage I and II the recurrence rate of BM after negative staging 
MRI is 6% within 5 years (majority within 2 years) (23). 
As even in early stages, risk for BM varies according to 
clinical characteristics, a score that predicts which patients 
are at an increased risk for BM would be useful. Besides 
clinical characteristics this score could for example include 
a miRNA signature in the near future, as certain miRNAs 
(involved in the regulation of several hundred genes) are 
associated with an increased risk for BM as was recently 
reviewed by Pedrosa et al. (24). MiRNA-328 for example 
was found to promote migration and subsequent BM 
formation in a NSCLC cell line, and was found to be 
overexpressed in both the primary and matched NSCLC 
BM. Similar results were found for miRNA-378 (24). The 
miRNAs are examined by microarray analysis of formalin-
fixed paraffin-embedded specimens of surgical resection 
tissues (25). 
The field of treatment of early stage NSCLC might 
change as multiple phase III trials are ongoing that compare 
adjuvant immunotherapy to placebo in NSCLC patients 
that had a complete resection of their NSCLC (PEARLS 
trial (NCT02504372), BR31 (NCT02273375) and ANVIL 
trial (NCT02595944). This is of interest regarding 
brain metastasis as the randomized phase III PACIFIC 
trial (NCT02125461), evaluating adjuvant durvalumab 
(programmed death ligand 1 antibody) versus placebo in 
stage III NSCLC treated with concurrent chemoradiation, 
showed that immunotherapy could have a role in reducing 
the incidence of BM after radical treatment (26). A 
secondary endpoint was the percentage of patients with 
distant metastases, this was reduced for the durvalumab 
group compared to the placebo group. Interestingly, after a 
median follow-up of 14.5 months the percentage of patients 
that developed BM was lower for durvalumab than for 
placebo (5.5% vs. 11%) (26). 
In conclusion, we applaud Hudson et al. for their 
research on this important topic in lung cancer. We agree 
that attention should be paid to the option of brain imaging 
during staging in early stage NSCLC, but that possible 
delay to surgery and costs should also be taken into account. 
As the chance of having BM is low in stage I disease, in our 
opinion screening in this stage should not be recommended. 
In stage II disease screening is debatable and could be 
considered in patients with adenocarcinoma histology and 
younger age. Screening in stage IIIA should be mandatory, 
and is also recommended in the guidelines. Better risk 
prediction models are needed, and we eagerly await the 
results of the adjuvant immunotherapy trials in early stage 
disease, as the role of immunotherapy in the prevention of 
BM development should also be evaluated in this setting. 
Acknowledgements 
None.
Footnote
Conflicts of Interest: AM Dingemans is advisory board 
member of Roche, Eli Lilly, Astra Zeneca, MSD and Pfizer. 
LE Hendriks is advisory board member of Boehringer-
Ingelheim and MSD. Another author has no conflicts of 
interest to declare.
References
1. Moro-Sibilot D, Smit E, de Castro Carpeno J, et al. Non-
small cell lung cancer patients with brain metastases 
treated with first-line platinum-doublet chemotherapy: 
Analysis from the European FRAME study. Lung Cancer 
2015;90:427-32.
2. Gaspar LE, Chansky K, Albain KS, et al. Time from 
treatment to subsequent diagnosis of brain metastases 
in stage III non-small-cell lung cancer: a retrospective 
review by the Southwest Oncology Group. J Clin Oncol 
2005;23:2955-61.
3. Andre F, Grunenwald D, Pujol JL, et al. Patterns of relapse 
of N2 nonsmall-cell lung carcinoma patients treated with 
preoperative chemotherapy: should prophylactic cranial 
irradiation be reconsidered? Cancer 2001;91:2394-400.
4. Carolan H, Sun AY, Bezjak A, et al. Does the incidence and 
outcome of brain metastases in locally advanced non-small 
cell lung cancer justify prophylactic cranial irradiation or 
S2171Journal of Thoracic Disease, Vol 10, Suppl 18 July 2018
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2018;10(Suppl 18):S2168-S2171jtd.amegroups.com
early detection? Lung Cancer 2005;49:109-15.
5. Ceresoli GL, Reni M, Chiesa G, et al. Brain metastases 
in locally advanced nonsmall cell lung carcinoma after 
multimodality treatment: risk factors analysis. Cancer 
2002;95:605-12.
6. Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally 
advanced non-small-cell lung cancer (NSCLC): ESMO 
Clinical Practice Guidelines for diagnosis, treatment and 
follow-up. Ann Oncol 2017;28:iv1-21.
7. Lim E, Baldwin D, Beckles M, et al. Guidelines on the 
radical management of patients with lung cancer. Thorax 
2010;65 Suppl 3:iii1-27.
8. Silvestri GA, Gonzalez AV, Jantz MA, et al. Methods 
for staging non-small cell lung cancer: Diagnosis and 
management of lung cancer, 3rd ed: American College 
of Chest Physicians evidence-based clinical practice 
guidelines. Chest 2013;143:e211S-50S.
9. NICE clinical guideline 121: The diagnosis and 
treatment of lung cancer. 2011:103-4. Available online: 
https://www.nice.org.uk/guidance/cg121/evidence/full-
guideline-181636957 
10. NCCN Guideline version 4. 2018 Non small cell lung 
cancer 2018 [cited 2018]. Version 4.2018. Available online: 
https://www.nccn.org/professionals/physician_gls/pdf/
nscl.pdf.
11. Schellinger PD, Meinck HM, Thron A. Diagnostic 
accuracy of MRI compared to CCT in patients with brain 
metastases. J Neurooncol 1999;44:275-81.
12. Suzuki K, Yamamoto M, Hasegawa Y, et al. Magnetic 
resonance imaging and computed tomography in the 
diagnoses of brain metastases of lung cancer. Lung Cancer 
2004;46:357-60.
13. Yokoi K, Kamiya N, Matsuguma H, et al. Detection 
of brain metastasis in potentially operable non-small 
cell lung cancer: a comparison of CT and MRI. Chest 
1999;115:714-9.
14. Levy A, Faivre-Finn C, Hasan B, et al. Diversity of 
brain metastases screening and management in non-
small cell lung cancer in Europe: Results of the European 
Organisation for Research and Treatment of Cancer Lung 
Cancer Group survey. Eur J Cancer 2018;93:37-46.
15. Hudson BJ, Crawford MB, Curtin JJ. Brain imaging in 
lung cancer patients without symptoms of brain metastases: 
a national survey of current practice in England. Clin 
Radiol 2015;70:610-3.
16. Steinmann D, Schafer C, van Oorschot B, et al. Effects of 
radiotherapy for brain metastases on quality of life (QoL). 
Prospective pilot study of the DEGRO QoL working 
party. Strahlenther Onkol 2009;185:190-7.
17. Hudson Z, Internullo E, Edey A, et al. Brain imaging 
before primary lung cancer resection: a controversial topic. 
Ecancermedicalscience 2017;11:749.
18. Balekian AA, Fisher JM, Gould MK. Brain Imaging for 
Staging of Patients With Clinical Stage IA Non-small 
Cell Lung Cancer in the National Lung Screening Trial: 
Adherence With Recommendations From the Choosing 
Wisely Campaign. Chest 2016;149:943-50.
19. Yohena T, Yoshino I, Kitajima M, et al. Necessity of 
preoperative screening for brain metastasis in non-small 
cell lung cancer patients without lymph node metastasis. 
Ann Thorac Cardiovasc Surg 2004;10:347-9.
20. Hochstenbag MM, Twijnstra A, Hofman P, et al. MR-
imaging of the brain of neurologic asymptomatic patients 
with large cell or adenocarcinoma of the lung. Does 
it influence prognosis and treatment? Lung Cancer 
2003;42:189-93.
21. Vernon J, Andruszkiewicz N, Schneider L, et al. 
Comprehensive Clinical Staging for Resectable Lung 
Cancer: Clinicopathological Correlations and the Role of 
Brain MRI. J Thorac Oncol 2016;11:1970-5.
22. Hendriks LE, Bootsma GP, de Ruysscher DK, et al. 
Screening for brain metastases in patients with stage 
III non-small cell lung cancer: Is there additive value of 
magnetic resonance imaging above a contrast-enhanced 
computed tomography of the brain? Lung Cancer 
2013;80:293-7.
23. Park HY, Kim YH, Kim H, et al. Routine screening by 
brain magnetic resonance imaging decreased the brain 
metastasis rate following surgery for lung adenocarcinoma. 
Lung Cancer 2007;58:68-72.
24. Pedrosa RMSM, Mustafa DAM, Aerts JGJV, et al. 
Potential Molecular Signatures Predictive of Lung Cancer 
Brain Metastasis. Front Oncol 2018;8:159.
25. Zhao S, Yu J, Wang L. Machine Learning Based 
Prediction of Brain Metastasis of Patients with IIIA-N2 
Lung Adenocarcinoma by a Three-miRNA Signature. 
Transl Oncol 2018;11:157-67.
26. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after 
Chemoradiotherapy in Stage III Non-Small-Cell Lung 
Cancer. N Engl J Med 2017;377:1919-29.
Cite this article as: Schoenmaekers JJ, Dingemans AM, 
Hendriks LE. Brain imaging in early stage non-small cell lung 
cancer: still a controversial topic? J Thorac Dis 2018;10(Suppl 
18):S2168-S2171. doi: 10.21037/jtd.2018.06.68
